Urgent.News

What's breaking now, across thousands of outlets.

AI

Iambic, an AI drug discovery specialist, banks $150M in an IPO

Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.”

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in AI

Production AI Governance: Moving from Ethical Checklists to Architectural Circuit Breakers

Production AI Governance: Moving from Ethical Checklists to Architectural Circuit Breakers The industry has entered a dangerous architectural phase: deploying non-deterministic, probabilistic models…

  • Shift from ethical checklists to architectural circuit breakers in AI governance.
  • Four hard invariants enforce runtime systems architecture for AI governance.
  • Single-Name Accountability Contract requires human responsibility for model parameters.

Samsung Brings Telecom Leaders Together to Shape the Future of AI-Native 6G

Samsung Electronics is bringing together leading telecommunications companies, technology developers, policymakers and academic experts in Silicon Valley to discuss how artificial intelligence and…

  • Samsung hosts Silicon Valley Future Wireless Summit 2026 on October 15
  • Summit focuses on AI integration in 6G network development
  • Over 100 industry leaders attend to explore wireless technology advancements

More from Thursday 15 October →